PLEKHF1 Activators encompass a diverse array of chemical compounds that indirectly heighten the functional activity of PLEKHF1 via distinct signaling pathways. Forskolin, by raising intracellular cAMP levels, indirectly fosters PLEKHF1's role in cellular processes through PKA activation, which may lead to phosphorylation events that modify PLEKHF1's activity. Sphingosine-1-phosphate, through its receptor-mediated signaling, could indirectly boost PLEKHF1 activity by engaging MAPK and PI3K/AKT pathways. Similarly, LY294002, as a PI3K inhibitor, and U0126, as a MEK1/2 inhibitor, could skew signaling in a manner that indirectly favors PLEKHF1 activation by altering the balance of pathway activities. SB203580 impacts PLEKHF1 by inhibiting p38 MAPK, potentially affecting stress response pathways in which PLEKHF1 may play a part. Thapsigargin and A23187, by perturbing intracellular calcium levels, could activate calcium-dependent signaling cascades, thereby influencing PLEKHF1 activity.
Epigallocatechin gallate and Genistein both function as kinase inhibitors, with the potential to modulate the cellularoxidative environment and tyrosine kinase-dependent signaling, respectively, creating conditions that may enhance PLEKHF1 activity. Phorbol 12-myristate 13-acetate (PMA) activates PKC, which could phosphorylate substrates within pathways involving PLEKHF1, leading to its enhanced function. Similarly, 8-Br-cAMP serves as a cAMP analog that activates PKA, potentially enhancing PLEKHF1 activity through phosphorylation events. Staurosporine, while being a broad-spectrum kinase inhibitor, could selectively influence PLEKHF1 by modulating the kinase activity within its signaling pathways. Collectively, these PLEKHF1 activators, through their targeted chemical interactions, serve to potentiate the activity of PLEKHF1 by affecting various signaling pathways and cellular processes, without necessitating direct activation or upregulation of the PLEKHF1 gene itself.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin activates adenylyl cyclase, resulting in increased cAMP levels, which in turn can activate PKA. PKA phosphorylates various proteins and could enhance PLEKHF1 function by phosphorylation or by modifying the cellular environment in which PLEKHF1 operates. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $43.00 $73.00 $126.00 $243.00 $530.00 $1259.00 | 11 | |
Epigallocatechin gallate is a potent antioxidant that inhibits several receptor tyrosine kinases and could reduce oxidative stress in cells, potentially maintaining an environment that supports PLEKHF1 activity. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA activates protein kinase C (PKC), which can phosphorylate target proteins and might induce signaling cascades that enhance PLEKHF1's function in cellular signaling pathways. | ||||||
D-erythro-Sphingosine-1-phosphate | 26993-30-6 | sc-201383 sc-201383D sc-201383A sc-201383B sc-201383C | 1 mg 2 mg 5 mg 10 mg 25 mg | $165.00 $322.00 $570.00 $907.00 $1727.00 | 7 | |
Sphingosine-1-phosphate acts through its receptors to activate intracellular signaling pathways, including those involving MAPK and PI3K/AKT, which could indirectly enhance PLEKHF1 activity through these pathways. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor, which could modulate PI3K/AKT signaling pathways, potentially relieving negative regulation on pathways where PLEKHF1 is a positive effector. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 inhibits MEK1/2 in the MAPK pathway, potentially shifting signaling dynamics to favor PLEKHF1 activation in pathways where it is involved in cellular stress responses. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 selectively inhibits p38 MAPK, which could modulate stress response pathways and indirectly enhance PLEKHF1 function, assuming PLEKHF1 operates within these pathways. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $136.00 $446.00 | 114 | |
Thapsigargin disrupts calcium homeostasis by blocking the sarcoplasmic/endoplasmic reticulum Ca2+ ATPase (SERCA), potentially increasing cytosolic calcium levels which may activate Ca2+-dependent signaling pathways influencing PLEKHF1 activity. | ||||||
A23187 | 52665-69-7 | sc-3591 sc-3591B sc-3591A sc-3591C | 1 mg 5 mg 10 mg 25 mg | $55.00 $131.00 $203.00 $317.00 | 23 | |
A23187 is a calcium ionophore that increases intracellular calcium concentration, possibly enhancing PLEKHF1 activity by activating calcium-dependent signaling pathways. | ||||||
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $45.00 $164.00 $200.00 $402.00 $575.00 $981.00 $2031.00 | 46 | |
Genistein is a tyrosine kinase inhibitor that may enhance PLEKHF1's function by modulating tyrosine kinase-dependent signaling pathways, potentially reducing competition or negative regulation on pathways involving PLEKHF1. | ||||||